What the FDA labels say about taking them together
Atazanavir/cobicistat and pravastatin
Atazanavir/cobicistat's FDA label of May 12, 2025 names pravastatin in its drug interactions section; the pravastatin label PlainMeds reads does not name atazanavir/cobicistat. The atazanavir/cobicistat label: “Coadministration of EVOTAZ with atorvastatin is not recommended. For HMG-CoA reductase inhibitors that are not contraindicated with EVOTAZ, start with the lowest recommended dose and titrate while monitoring for safety …”
Check it at the source: the atazanavir/cobicistat FDA label on DailyMed (effective May 12, 2025, E.R. Squibb & Sons, L.L.C.); the pravastatin FDA label on DailyMed (effective July 31, 2026, Apotex Corp.).
What does the atazanavir/cobicistat label say about pravastatin?
Atazanavir/cobicistat label, drug interactionsConcomitant Drug Class/Specific Drugs: Other HMG-CoA reductase inhibitors: atorvastatin, fluvastatin, pravastatin, rosuvastatin; Effect b on Concentration: ↑ HMG-CoA reductase inhibitors; Clinical Comment: Coadministration of EVOTAZ with atorvastatin is not recommended. For HMG-CoA reductase inhibitors that are not contraindicated with EVOTAZ, start with the lowest recommended dose and titrate while monitoring for safety (e.g., myopathy). Dosage recommendations with rosuvastatin are as follows. Rosuvastatin dose should not exceed 10 mg/day.
Source: FDA drug label (EVOTAZ), NDA206353 (Bristol), as published by E.R. Squibb & Sons, L.L.C., effective May 12, 2025 (SPL set 83db29d7-5d85-49d6-8cb6-740473365cf8), via openFDA; the full label on DailyMed
What does the pravastatin label say about atazanavir/cobicistat?
Pravastatin's label (effective July 31, 2026) does not name atazanavir/cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (PRAVASTATIN SODIUM), Apotex Corp., effective July 31, 2026 (SPL set dcf45e4f-b46e-6fbb-b67a-2ff619ab1780), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir/cobicistat | Pravastatin | |
|---|---|---|
| Labeled for | HIV | Heart attack and coronary artery disease, High cholesterol, High triglycerides |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $52.05 per tablet 300 mg-150 mg tablet | $0.058 per tablet 20 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once